文献速递认知障碍与痴呆

血浆P-tau217与早期阿尔茨海默病Tau PET的关联

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease.
PubMed 文献 · JAMA Neurol · 2021-01-01

这项队列研究纳入490名认知健康、主观认知下降或轻度认知障碍参与者,比较血浆P-tau217与脑脊液P-tau217及Tau PET在早期AD中的变化时序。发现血浆P-tau217在Aβ异常但Tau PET阴性的认知未受损者中已升高,且纵向Tau PET增速更高,提示其可作为早期AD脑病理的血浆标志物。

要点

  • 血浆P-tau217在Aβ-PET阳性但Tau PET阴性的认知未受损者中已升高。
  • 事件模型预测血浆与脑脊液P-tau217早于内嗅皮层Tau PET信号变化。
  • 基线血浆P-tau217异常者随访中内嗅皮层Tau PET摄取增加更快。

核心结论

  • 血浆P-tau217在AD早期临床前阶段即升高,此时Tau PET尚无法检测到不可溶Tau聚集。
  • 血浆P-tau217有望作为早期AD脑病理的血浆生物标志物。

研究设计与样本

  • 队列研究纳入BioFINDER-2中认知健康对照225人、主观认知下降89人、轻度认知障碍176人,共490人。
  • 其中111人有2或3次Tau PET扫描的亚队列。

主要发现

  • 认知未受损者中Aβ-PET阳性但内嗅皮层Tau PET阴性组血浆P-tau217中位数2.2 pg/mL(IQR 1.5-2.9),高于Aβ-PET阴性/Tau PET阴性组的0.7 pg/mL(IQR 0.3-1.4)。
  • 血浆P-tau217与Tau PET不一致的认知未受损者中,94.7%(36例)为血浆P-tau217阳性/Tau PET阴性,5.3%(2例)为血浆P-tau217阴性/Tau PET阳性。
  • 横断面事件模型预测认知未受损者和轻度认知障碍者中血浆与脑脊液P-tau217均早于内嗅皮层Tau PET信号变化,随后出现更广泛皮层Tau PET改变。
  • 非线性样条模型显示血浆与脑脊液P-tau217在较低Aβ-PET值时即升高,早于Tau PET指标。
  • 基线Tau PET正常者中,基线血浆P-tau217异常者内嗅皮层Tau PET纵向增加速率更高(中位SUVr 0.029 [IQR -0.006至0.041] vs -0.001 [IQR -0.021至0.020];Mann-Whitney U,P=0.02)。

临床怎么用

  • 血浆P-tau217可用于早期识别AD临床前阶段的脑病理变化,尤其在Tau PET尚未阳性时。
  • 对认知未受损但Aβ异常者,血浆P-tau217升高提示后续Tau沉积风险更高,可辅助监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is an urgent need for inexpensive and minimally invasive blood biomarkers for Alzheimer disease (AD) that could be used to detect early disease changes. OBJECTIVE: To assess how early in the course of AD plasma levels of tau phosphorylated at threonine 217 (P-tau217) start to change compared with levels of established cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers of AD pathology. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included cognitively healthy control individuals (n = 225) and participants with subjective cognitive decline (n = 89) or mild cognitive impairment (n = 176) from the BioFINDER-2 study. Participants were enrolled at 2 different hospitals in Sweden from January 2017 to October 2019. All study participants underwent plasma P-tau217 assessments and tau- and amyloid-β (Aβ)-PET imaging. A subcohort of 111 participants had 2 or 3 tau-PET scans. MAIN OUTCOMES AND MEASURES: Changes in plasma P-tau217 levels in preclinical and prodromal AD compared with changes in CSF P-tau217 and PET measures. RESULTS: Of 490 participants, 251 were women (51.2%) and the mean (SD) age was 65.9 (13.1) years. Plasma P-tau217 levels were increased in cognitively unimpaired participants with abnormal Aβ-PET but normal tau-PET in the entorhinal cortex (Aβ-PET+/ tau-PET- group vs Aβ-PET-/ tau-PET- group: median, 2.2 pg/mL [interquartile range (IQR), 1.5-2.9 pg/mL] vs 0.7 pg/mL [IQR, 0.3-1.4 pg/mL]). Most cognitively unimpaired participants who were discordant for plasma P-tau217 and tau-PET were positive for plasma P-tau217 and negative for tau-PET (P-tau217+/tau-PET-: 36 [94.7%]; P-tau217-/tau-PET+: 2 [5.3%]). Event-based modeling of cross-sectional data predicted that in cognitively unimpaired participants and in those with mild cognitive impairment, both plasma and CSF P-tau217 would change before the tau-PET signal in the entorhinal cortex, followed by more widespread cortical tau-PET changes. When testing the association with global Aβ load in nonlinear spline models, both plasma and CSF P-tau217 were increased at lower Aβ-PET values compared with tau-PET measures. Among participants with normal baseline tau-PET, the rates of longitudinal increase in tau-PET in the entorhinal cortex were higher in those with abnormal plasma P-tau217 at baseline (median standardized uptake value ratio, 0.029 [IQR, -0.006 to 0.041] vs -0.001 [IQR, -0.021 to 0.020]; Mann-Whitney U, P = .02). CONCLUSIONS AND RELEVANCE: In this cohort study, plasma P-tau217 levels were increased during the early preclinical stages of AD when insoluble tau aggregates were not yet detectable by tau-PET. Plasma P-tau217 may hold promise as a biomarker for early AD brain pathology.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Janelidze S, Berron D, Smith R, et al. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurol. 2021. PMID: 33165506. doi:10.1001/jamaneurol.2020.4201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。